Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and feasibility of the Exablate Model
4000 Type 2 system when used as a tool to open the blood-brain-barrier (BBB) in subjects with
recurrent glioblastoma (rGBM) undergoing carboplatin monotherapy.